Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHYSICIAN FEE SCHEDULE PATHOLOGY PAYMENT COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · fourth_quarter · 4T
Medicare reimbursement for laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2015 · fourth_quarter · Q4
Source: Senate LDA
| REDPATH INTEGRATED PATHOLOGY INC |
| 9 |
| 2008–2010 |
| CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION | 8 | 2013–2015 |
| NOVAVISION INC | 5 | 2006–2008 |
| PHYSICIAN FEE SCHEDULE PATHOLOGY PAYMENT COALITION | 4 | 2013–2015 |
| ABBOTT LABORATORIES | 3 | 2011 |
| DRUGS OF ABUSE TESTING COALITION | 3 | 2011 |
| INOVISE MEDICAL, INC. | 2 | 2007 |
| PLC MEDICAL SYSTEMS | 2 | 1999 |
| SANOFI-AVENTIS U.S. INC. | 2 | 2009 |
| TEARLAB CORP | 2 | 2011 |
| BG MEDICINE | 1 | 2013 |
| CYTOMEDIX, INC. | 1 | 2008 |
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590. Seeking TRICARE coverage for laboratory-developed tests.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590. Seeking TRICARE coverage for laboratory-developed tests.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
American Middle Class Tax (AMT) Relief Act of 2007
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590. Seeking TRICARE coverage for laboratory-developed tests.
American Middle Class Tax (AMT) Relief Act of 2007
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
American Middle Class Tax (AMT) Relief Act of 2007
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
American Middle Class Tax (AMT) Relief Act of 2007
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
American Middle Class Tax (AMT) Relief Act of 2007
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
American Middle Class Tax (AMT) Relief Act of 2007
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699, S. 1220 and H.R. 3590.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220. Seeking TRICARE coverage for laboratory-developed tests.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220. Seeking TRICARE coverage for laboratory-developed tests.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220..
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220..
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed test; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: REDPATH INTEGRATED PATHOLOGY, INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
Medicare reimbursement for clinical laboratory services; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220. Seeking TRICARE coverage for laboratory-developed tests.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: COALITION FOR 21ST CENTURY MEDICINE · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests; seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220.
Patient Access to Critical Lab Tests Act
Client: GENOMIC HEALTH INC · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests, seeking to advance H.R. 1699 and S. 1220. Seeking TRICARE coverage for laboratory-developed tests.
Affordable Health Choices Act
Client: SANOFI-AVENTIS U.S. INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA approval of follow on biologics, including S. 1679
Affordable Health Choices Act
Client: SANOFI-AVENTIS U.S. INC. · Firm: MCDERMOTT WILL & SCHULTE LLP
FDA approval of follow on biologics, including S. 1679
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · fourth_quarter · 4T
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2015 · fourth_quarter · 4T
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PHYSICIAN FEE SCHEDULE PATHOLOGY PAYMENT COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · third_quarter · Q3
Medicare reimbursement for laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · third_quarter · Q3
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2015 · third_quarter · Q3
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · second_quarter · Q2
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2015 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2015 · first_quarter · Q1
Medicare regulation of clinical laboratories.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · first_quarter · Q1
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2015 · first_quarter · Q1
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2015 · first_quarter · Q1
Medicare reimbursement for laboratory tests.
Issues concerning regulation of laboratory tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · 1A
Medicare competitive bidding program for durable medical equipment and supplies. Medicare payments for laboratory services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · 1A
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · fourth_quarter · Q4
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2014 · fourth_quarter · Q4
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2014 · fourth_quarter · Q4
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · fourth_quarter · Q4
Issues concerning regulation of laboratory tests.
Medicare reimbursement for laboratory tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2014 · third_quarter · Q3
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · third_quarter · Q3
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2014 · third_quarter · Q3
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · third_quarter · Q3
Issues concerning regulation of laboratory tests.
Medicare reimbursement for laboratory tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2014 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · second_quarter · Q2
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2014 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · second_quarter · Q2
Medicare reimbursement for laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Medicare competitive bidding program for durable medical equipment and supplies. Medicare payments for laboratory services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2014 · first_quarter · Q1
Medicare reimbursement for laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHYSICIAN FEE SCHEDULE PATHOLOGY PAYMENT COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Medicare reimbursement for laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Issues concerning regulation of laboratory tests.
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Medicare reimbursement for laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2013 · fourth_quarter · Q4
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PHYSICIAN FEE SCHEDULE PATHOLOGY PAYMENT COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · RR
Medicare reimbursement for laboratory tests.
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
Medicare reimbursement for laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLINICAL LABORATORY FEE SCHEDULE REFORM COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · RR
Medicare reimbursement for laboratory tests.
BG MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2013 · third_quarter · Q3
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2013 · second_quarter · Q2
Medicare competitive bidding program for durable medical equipment and supplies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · second_quarter · Q2
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2013 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2013 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2013 · second_quarter · Q2
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2013 · first_quarter · Q1
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2013 · first_quarter · Q1
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2013 · first_quarter · Q1
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2013 · first_quarter · Q1
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2012 · fourth_quarter · Q4
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2012 · fourth_quarter · Q4
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2012 · fourth_quarter · Q4
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
FDA regulation of laboratory-developed tests.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2012 · fourth_quarter · Q4
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2012 · third_quarter · Q3
Issues concerning regulation of laboratory tests.
FDA regulation of laboratory-developed tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2012 · third_quarter · Q3
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2012 · third_quarter · Q3
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2012 · third_quarter · Q3
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2012 · second_quarter · Q2
FDA regulation of laboratory-developed tests.
FDA regulation of laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2012 · second_quarter · Q2
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2012 · second_quarter · Q2
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2012 · second_quarter · Q2
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2012 · first_quarter · Q1
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests. Seeking TRICARE coverage for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2012 · first_quarter · Q1
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2012 · first_quarter · Q1
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · 4A
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
TEARLAB CORP via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests. Seeking TRICARE coverage for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · Q4
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2011 · third_quarter · Q3
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests. Seeking TRICARE coverage for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DRUGS OF ABUSE TESTING COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · third_quarter · Q3
Advocacy on Medicare reimbursement codes and payment rates for qualitative drug screen testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · third_quarter · Q3
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2011 · third_quarter · Q3
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · third_quarter · Q3
Issues related to Section 340B of the Public Health Service Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
TEARLAB CORP via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · RR
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule
ABBOTT LABORATORIES via MCDERMOTT WILL & SCHULTE LLP
2011 · fourth_quarter · RR
Medicare reimbursement matters concerning diagnostic laboratory test services under the Clinical Laboratory Fee Schedule
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Issues affecting Medicare Reimbursement for advanced laboratory diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROTHROMBIN-TIME SELF TESTING COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Seeking Medicare coverage and reimbursement for home anticoagulation services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests. Seeking TRICARE coverage for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DRUGS OF ABUSE TESTING COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Advocacy on Medicare reimbursement codes and payment rates for qualitative drug screen testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Issues concerning regulation of laboratory tests.
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · Q2
Issues related to Section 340B of the Public Health Service Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
DRUGS OF ABUSE TESTING COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · second_quarter · RR
Advocacy on Medicare reimbursement codes and payment rates for qualitative drug screen testing
ROCHE DIAGNOSTICS CORPORATION, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
Issues affecting Medicare Reimbursement for advanced laboratory diagnostics.
Issues affecting FDA regulation of advanced laboratory diagnostics.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PROTHROMBIN-TIME SELF TESTING COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
Seeking Medicare coverage and reimbursement for home anticoagulation services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENOMIC HEALTH INC via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests. Seeking TRICARE coverage for laboratory-developed tests.
Medicare reimbursement for laboratory-developed tests.
FDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR 21ST CENTURY MEDICINE via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
Issues concerning Medicare reimbursement for advanced diagnostic laboratory tests and section 3113 of the Affordable Care Act.
Issues concerning regulation of laboratory tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN, INC. via MCDERMOTT WILL & SCHULTE LLP
2011 · first_quarter · Q1
Issues related to Section 340B of the Public Health Service Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
DIABETES ACCESS TO CARE COALITION via MCDERMOTT WILL & SCHULTE LLP
2010 · fourth_quarter · 4A
Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE